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Similar to other long-term studies, the results of the
Munich 15-follow-up study, which compared the out-
come of first hospitalised patients with schizophrenic,
schizoaffective and affective psychoses, demonstrated that
on average the course and outcome of schizophrenia is
less favourable than that of affective and schizoaffective
disorders. Furthermore, it was shown that at least a sub-
group of schizophrenic patients generally have a poor out-
come. Negative symptoms occurred in all functional
psychoses but were more frequent and prominent in the
schizophrenic group than in the two other diagnostic
groups at any time of assessment. Narrower concepts of
negative symptoms, conceptualised as the deficit syn-
drome, seem to be specific for schizophrenia and appear
quite rarely in patients with affective psychosis. Especially
the long-term outcome appears to be predominantly char-
acterised by negative symptoms/the deficit syndrome in
the sense that the negative symptoms/deficit syndrome
differentiate much better the schizophrenic from the
affective/schizoaffective patients than the positive symp-
toms. While there is such a clear signal that the increase of
negative symptoms is the core symptomatology of schizo-
phrenia, the question has not yet been fully answered
whether cognitive disturbances, which are generally seen
as the most relevant vulnerability indicator of schizophre-
nia, progressively deteriorate over the long-term course of
schizophrenia.
Altogether there is evidence to support Kraepelin's origi-
nal hypothesis that schizophrenia has a worse outcome
than affective psychosis. A subgroup of schizophrenic
patients seem to have a more deleterious long-term course
and outcome in terms of functional incapacity and psy-
chopathological disturbances. Particularly negative symp-
toms, and possibly also cognitive disturbances,
characterise patients with an unfavourable course.
How does this relate to the current theories and empirical
data on the aetiopathogensis of schizophrenia? The neu-
rodevelopmental hypothesis, which is very broadly
accepted, can explain the origin of the disease in terms of
vulnerability. However, at least in a subgroup of schizo-
phrenic patients with a more chronic deteriorating course,
the hypothesis of a progressive neurotoxic/neurodegener-
ative process has to be taken into consideration. Structural
MRI data from several research groups suggest evidence
for structural brain changes in the course of the disease.
These data are in accordance with our Munich MRI data-
base, which includes altogether data from 400 patients
and controls. Additional analyses show that the brain
alterations demonstrated by MRI analyses are associated
among others with negative symptoms. Of great interest is
the link between genetic abnormalities of schizophrenic
patients and brain alterations shown by MRI, which will
allow a better understanding of the so-called first and sec-
ond hit. Another view of the possible progressive biologi-
cal course of schizophrenia is related to the
neurotransmitter systems, especially to the glutamate sys-
tem. The hypothesis of a glutamate "intoxication", which
might explain the progressive deterioration, was suggested
on the basis of animal research. Last but not least immu-
nological alterations should be investigated much more
carefully. Findings from our own group showing the ben-
efits of a comedication of Cox-II-inhibitors and novel
neuroleptics are very promising in this respect.
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